Primary Care
Physician perspectives on preventive care, chronic disease management, and evidence-based primary care practice.
Recent Discussions
In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?
In the ideal world, we would tailor the need for booster shots based on whether or not a patient achieves an appropriate immunologic response and maintains that response for long periods of time. This would include both seroconversion and T-cell-mediated immunity. However, we have neither routine no...
Do you recommend that patients undergoing radiation treatment get a COVID vaccine booster?
Yes, we are recommending the third dose booster for our patients who are moderately or severely immunosuppressed. In addition to anyone getting chemoradiation, I would consider anyone treated with large field radiation to begin that category. As for timing, would start before treatment ideally. As f...
How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?
Like most other treatments, I've tried to triage use of REGEN-COV post-exposure prophylaxis (PEP) based on the other risk factors that a patient has:The NEJM study published by O'Brien et al. PMID 34347950 did show marked benefit in REGEN-COV post-exposure prophylaxis vs. placebo in the (a) decreasi...
Would you pursue temporal artery biopsy in patients with PMR who develop cranial GCA symptoms and have been on PMR dose steroids for one year?
This is a challenging question. While the literature would suggest that the rate of positive biopsies after 14 days of prednisone have similar positivity to those done before 14 days (Achkar et al., PMID 8185147, retrospective study with potential for bias), there is no data to my knowledge regardin...
How would you manage early-stage low rectal cancer in a patient unable or unwilling to undergo surgery?
This patient may have multiple non-TME alternative options. Trans-anal excision with or without post-op CRT based upon pathological risk factors would be one option. Alternatively, CRT as part of a non-operative management/watch and wait strategy is also associated with favorable outcomes. Here are ...
How do you determine if a patient is safe to drive after having a PCA infarct?
In many patients with PCA infarction, the answer is clear, that they cannot safely drive. In my state, the law requires 140 degrees of lateral vision for driving privileges, not met by patients with homonymous hemianopsias. These patients need to be told that they cannot legally drive, and this need...
Is there a role for immunosuppression in patients with triple positive antiphospholipid antibodies who do not meet the clinical criteria for APS?
Currently, there are no “clinical” nor “diagnostic” criteria for antiphospholipid syndrome (APS). I suspect your question refers to patients not meeting the Sapporo APS “classification criteria.”There are two primary ways that patients with triple-positive antiphospholipid antibodies (aPLs: anticard...
What hematologic conditions are contraindications for a COVID vaccine?
The short answer is that a history of severe allergic reaction is really the only contraindication to COVID-19 vaccination. Perhaps, patients with systemic mastocytosis might be at increased risk of allergic reaction but I'm not aware of data to support that.The longer answer is a question of timing...
How do you diagnose and treat patients who develop uveitis while on bisphosphonate therapy for osteoporosis?
Ocular inflammation, usually anterior uveitis, can occur as a consequence of bisphosphonate therapy. Virtually always, the bisphosphonate is one that is given intravenously and the ocular inflammation begins a day or two after the treatment. Furthermore, the inflammation is generally self-limited; i...
What is your steroid-sparing agent of choice to treat GCA given the current tocilizumab shortage?
If at all possible, I continue to use tocilizumab as a glucocorticoid sparing agent for patients with giant cell arteritis. Given the results of the GIACTA trial, the Villiger trial, and lots of observational data, it is clear that tocilizumab provides efficacy in terms of reducing risk of relapse a...